Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

580 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group.
Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G, Noens L, Szer J, Ganser A, O'Brien C, Matcham J, Barge A. Heil G, et al. Among authors: sanz ma. Blood. 1997 Dec 15;90(12):4710-8. Blood. 1997. PMID: 9389686 Free article. Clinical Trial.
A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia.
Archimbaud E, Ottmann OG, Yin JA, Lechner K, Dombret H, Sanz MA, Heil G, Fenaux P, Brugger W, Barge A, O'Brien-Ewen C, Matcham J, Hoelzer D. Archimbaud E, et al. Among authors: sanz ma. Blood. 1999 Dec 1;94(11):3694-701. Blood. 1999. PMID: 10572081 Free article. Clinical Trial.
Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia--a randomized, placebo-controlled, double-blind safety and efficacy study.
Geissler K, Yin JA, Ganser A, Sanz MA, Szer J, Raghavachar A, Hoelzer D, Martinez C, Taylor K, Kanz L, To LB, Archimbaud E. Geissler K, et al. Among authors: sanz ma. Ann Hematol. 2003 Nov;82(11):677-83. doi: 10.1007/s00277-003-0737-7. Epub 2003 Oct 3. Ann Hematol. 2003. PMID: 14530872 Clinical Trial.
Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.
Sanz MA, Montesinos P, Rayón C, Holowiecka A, de la Serna J, Milone G, de Lisa E, Brunet S, Rubio V, Ribera JM, Rivas C, Krsnik I, Bergua J, González J, Díaz-Mediavilla J, Rojas R, Manso F, Ossenkoppele G, González JD, Lowenberg B; PETHEMA and HOVON Groups. Sanz MA, et al. Blood. 2010 Jun 24;115(25):5137-46. doi: 10.1182/blood-2010-01-266007. Epub 2010 Apr 14. Blood. 2010. PMID: 20393132 Free article. Clinical Trial.
Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group.
De Botton S, Dombret H, Sanz M, Miguel JS, Caillot D, Zittoun R, Gardembas M, Stamatoulas A, Condé E, Guerci A, Gardin C, Geiser K, Makhoul DC, Reman O, de la Serna J, Lefrere F, Chomienne C, Chastang C, Degos L, Fenaux P. De Botton S, et al. Blood. 1998 Oct 15;92(8):2712-8. Blood. 1998. PMID: 9763554 Free article. Clinical Trial.
A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group.
Sanz MA, Martín G, Rayón C, Esteve J, González M, Díaz-Mediavilla J, Bolufer P, Barragán E, Terol MJ, González JD, Colomer D, Chillón C, Rivas C, Gómez T, Ribera JM, Bornstein R, Román J, Calasanz MJ, Arias J, Alvarez C, Ramos F, Debén G. Sanz MA, et al. Blood. 1999 Nov 1;94(9):3015-21. Blood. 1999. PMID: 10556184 Free article. Clinical Trial.
Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
Ferrant A, Labopin M, Frassoni F, Prentice HG, Cahn JY, Blaise D, Reiffers J, Visani G, Sanz MA, Boogaerts MA, Löwenberg B, Gorin NC. Ferrant A, et al. Among authors: sanz ma. Blood. 1997 Oct 15;90(8):2931-8. Blood. 1997. PMID: 9376573 Free article.
A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group.
Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Makhoul PC, Travade P, Solary E, Fegueux N, Bordessoule D, Miguel JS, Link H, Desablens B, Stamatoullas A, Deconinck E, Maloisel F, Castaigne S, Preudhomme C, Degos L. Fenaux P, et al. Blood. 1999 Aug 15;94(4):1192-200. Blood. 1999. PMID: 10438706 Free article. Clinical Trial.
580 results